Table 1.

CD16 expression by NK cells of cancer patients receiving recombinant human IL-18

	Absolute number of CD16 + NK cells per μL
Week 1	96 ± 35
Week 2	125 ± 35
Week 4	100 ± 35
Week 5	105 ± 23

Ten patients were given weekly intravenous infusions of recombinant human IL-18 at doses of 100 (4 patients), 1,000 (3 patients), or 2,000 (3 patients) μg/kg as previously described [13]. Blood samples were obtained prior to IL-18 infusions on weeks 1, 2, 4, and 5 of study, and the absolute number of CD16 + NK cells was determined as described in Materials and Methods. Results shown are mean ± SE of data from 9 patients. One patient did not have a sample obtained at baseline (week 1) and has been excluded from the analysis